COMP <GO>
UTHR vs JNJ // EV/EBITDA & P/E VALUATION
United Therapeutics Corporation (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: UTHR 11
— JNJ 3
▲ EV/EBITDA & P/E VALUATION LEADER: UTHR
LAST: $598.72 (+0.87%) • MKT CAP: $25.46B
valuation
12.5x
LAST: $273.20 (-0.73%) • MKT CAP: $662.49B
valuation
18.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UTHR VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UTHR | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 87.90% | 67.90% | +20.00 | UTHR | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.10% | 25.50% | -5.40 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 12.5x | 18.5x | -6.00 | UTHR | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 2.97% | +1.12 | UTHR | /fcf-yield <GO> |
| Operating Margin | 46.90% | 34.70% | +12.20 | UTHR | /operating-margins <GO> |
| Net Profit Margin | 41.90% | 28.50% | +13.40 | UTHR | /net-margins <GO> |
| Revenue Growth (YoY) | 10.60% | 6.00% | +4.60 | UTHR | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 22.52 | 5.59 | +16.93 | UTHR | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 8/9 | +1.00 | UTHR | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.70% | 7.20% | -0.50 | UTHR | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 70.1 | 60.4 | +9.77 | UTHR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.08 | -0.13 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 17.8x | 23.0x | -5.20 | UTHR | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $25.46B | $662.49B | -$637.03B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UTHR REV | JNJ REV | UTHR GROSS % | JNJ GROSS % | UTHR FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.18B | $94.19B | 87.9% | 67.9% | $1.04B | $19.70B |
| FY 2024 | $2.88B | $88.82B | 89.2% | 69.1% | $1.08B | $19.84B |
| FY 2023 | $2.33B | $85.16B | 44.0% | 44.0% | $873.3M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UTHR // BETA 0.95
JNJ // BETA 1.08